Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2023Cited by 830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeLorenzo Gerratana, Grazia Arpino, Debora Basile et al.|Cancer Treatment Reviews|2018Cited by 282
CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Sabino De Placido et al.|The Lancet|2015Cited by 201